logo
  

Valneva, Pfizer Report Positive Phase 2 Pediatric Data For Lyme Disease Vaccine Candidate, VLA15

Valneva SE (VLA), a specialty vaccine company, and Pfizer Inc. (PFE) reported Tuesday positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Based on these new results, the companies plan to proceed with inclusion of pediatric participants in their planned Phase 3 trial.

The trial will evaluate VLA15 in adults and pediatric subjects 5 years of age and above and is expected to be initiated in the third quarter of 2022, subject to regulatory approval.

The Phase 2 trial, VLA15-221, is the first clinical study with VLA15 which enrolled a pediatric population between 5 and 17 years old. It compared the immunogenicity and safety of VLA15 after administration of two or three primary series doses in groups aged 5-11, 12-17 and 18-65 years.

In pediatric participants who received VLA15 in either the two-dose schedule or three-dose schedule, VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested.

Like in adults, the immunogenicity and safety data support a three-dose primary vaccination schedule in pediatric participants in the Phase 3 study.

The companies noted that the safety and tolerability profile observed in the 5- to 17-year age group was similar to the previously reported profile in adult participants. No vaccine-related serious adverse events or SAEs were observed.

Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Russia's manufacturing activity grew at the fastest pace in three-and-a-half years in September, supported by increases in production and new orders, survey data from S&P Global showed on Monday. The factory Purchasing Managers' Index posted 52.0 in September, up from 51.7 in August. A score above... India's manufacturing sector growth slowed moderately in September but the overall growth remained robust, survey data published by S&P Global showed on Monday. The manufacturing Purchasing Managers' Index fell to 55.1 in September from 56.2 in August. The score was also below economists' forecast... Final manufacturing Purchasing Managers' survey results from the euro area and the UK are the major reports due on Monday. At 2.30 am ET, the Federal Statistical Office is scheduled to issue Swiss consumer price data for September. Inflation is forecast to remain unchanged at 3.5 percent.
Follow RTT